New pill combined with chemotherapy shows potential to eradicate pancreatic cancer in some patients

A new once-a-day pill, daraxonrasib, has shown promising results, eradicating pancreatic cancer in some patients when combined with chemotherapy in a clinical trial.

WTX News

•6 min read
0

/

New pill combined with chemotherapy shows potential to eradicate pancreatic cancer in some patients

Get you up to speed: Major breakthrough after pill wipes out deadliest cancer in patients | News World

A clinical trial in Barcelona has demonstrated that the once-daily pill daraxonrasib, combined with chemotherapy, has eradicated pancreatic cancer in some patients. In the trial, 8.2% of patients experienced complete responses, while 76.6% were alive one year after treatment.

The phase one/two clinical trial involved 61 patients and demonstrated that combined treatment with daraxonrasib and chemotherapy led to tumour shrinkage or disappearance in 60.7% of participants over an 18-month follow-up period. A larger phase-three study is set to begin in the US, with some sites in Europe possibly still accepting additional patients.

The UK Government has been urged to increase investment in pancreatic cancer research and establish a rapid pathway for promising new treatments, as emphasised by Dr Madina Kara of Pancreatic Cancer UK following the successful trial of daraxonrasib. Cancer Research UK chief executive Michelle Mitchell noted that more trials are necessary before the treatment can be considered for NHS use, highlighting the ongoing need for further research despite this breakthrough.

What remains unclear — The impact of daraxonrasib on long-term survival beyond the initial one-year follow-up remains to be established.

New pill combined with chemotherapy shows potential to eradicate pancreatic cancer in some patients

FBAR1R Healthcare, treatment, supplements. Handful of white round pills in female patients palm, woman arm holding heap of small round
A new pill is ‘closest thing to a cure’ for pancreatic cancer (Picture: Alamy Stock Photo)

A new once-a-day pill has wiped out pancreatic cancer in some patients in a huge breakthrough for treatment.

One in 12 patients had their advanced pancreatic cancer completely eradicated using the drug combined with chemotherapy, according to a clinical trial.

The lead medic on the trial said the results represented the ‘closest’ thing to a ‘cure’ for some patients.

Draxonrasib, when used alongside chemotherapy, could increase the proportion of patients alive after one year compared to standard treatment.

In May, the drug was found to almost double survival time for patients with aggressive and advanced pancreatic cancer compared to chemo alone.

The pill also caused fewer side effects so experts are hailing it as a breakthrough in treating people with the disease.

Sign up for all of the latest stories

EMBARGOED TO 2301 THURSDAY NOVEMBER 19 Undated handout photo issued by Memorial Sloan Kettering Cancer Centre of CT scans before (left) and after treatment with Daraxonrasib plus chemotherapy (gemcitabine and nabpaclitaxel) showing multiple tumours that are no longer visible following treatment in a patient with matastic pancreatic cancer (Yellow arrows indicate the tumours visible before treatment). A once-a-day pill for advanced pancreatic cancer has eradicated the disease in some patients when combined with chemotherapy, according to a clinical trial. A new study being presented at the European Organisation For Research And Treatment Of Cancer meeting in Barcelona shows that combining daraxonrasib with chemotherapy can have dramatic effects. Issue date: Tuesday November 17, 2026. PA Photo. Photo credit should read: Dr Michael May/Dr Wungki Park/Memorial Sloan Kettering Cancer Center/Press Association NOTE TO EDITORS: This handout photo may only be used for editorial reporting purposes for the contemporaneous illustration of events, things or the people in the image or facts mentioned in the caption. Reuse of the picture may require further permission from the copyright holder.
CT scans before (left) and after treatment with Daraxonrasib plus chemotherapy show reduced tumours
(Picture: Dr Michael May/Dr Wungki Park/Memorial Sloan Kettering Cancer Center/Press Association)

Daraxonrasib works by locking onto the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumours and continuously signals cancer cells to grow.

By shutting this off, the drug can prevent tumours from spreading.

In the new study, presented at the European Organisation for Research and Treatment of Cancer in Barcelona, tumours shrank or disappeared in 60.7% of patients given daraxonrasib and chemotherapy.

This included complete responses in 8.2% of patients over a typical follow-up of 18 months, meaning their tumours were no longer detectable.

Overall, tumours stopped growing in 90.2% of all 61 patients studied (the disease control rate) over a typical period of 18 months.

One year after treatment, 76.6% of patients were still alive. This compares to around 40% to 45% of patients when they are given chemotherapy alone.

It also took 12.8 months on average for tumours to return or start growing again when the whole patient group was taken into account, the phase one/two clinical trial showed.

Dr Wungki Park, oncologist at Memorial Sloan Kettering Cancer Centre in New York, who presented the findings, told the Press Association he had never seen such responses, adding it represents ‘a massive, massive breakthrough’ in treating pancreatic cancer.

London. A once-daily pill helped almost double survival time for patients with an aggressive and advanced form of pancreatic cancer when compared to chemotherapy, a trial has found. The drug also caused fewer side-effects, with experts hailing daraxonrasib as ” landscape=”” for=”” people=”” with=”” the=”” disease.=”” issue=”” date:=”” sunday=”” may=”” pa=”” photo.=”” photo=”” credit=”” should=”” read:=”” jeff=”” moore=”” wire=”” decoding=”async” loading=”lazy”/>
One in 12 patients had their cancer wiped out (Picture: Jeff Moore/PA Wire)

‘In about one in 12 patients, it (the cancer) completely disappeared,’ he said. ‘And then with such a long follow-up, this is real. We’ve never seen such a thing.’

Asked if the one in 12 patients whose tumours could not be seen were regarded as cured, he said: ‘This is the closest to cure.

‘This is almost at the discovery level, we have never seen 8% complete response in metastatic pancreatic cancer, you don’t see that….

‘The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission …. it’s incredible.’

He said longer-term survival data would come as the trial progressed, but there is ‘some survival signal here, which is very strong’, with 76.6% of patients alive after one year.

Fewer than 5% of patients in the trial discontinued treatment, which is regarded as low.

Dr Park said cancer does frequently develop resistance to drug treatment but ‘we’re delaying that as much as possible’ through the new combined treatment.

The final phase-three study in the US has enough patients but some sites in Europe may have space.

Dr Madina Kara, head of research at Pancreatic Cancer UK, said: ‘Half of people with pancreatic cancer die within three months of diagnosis and their loved ones would give anything to spend more precious time with them.

‘This is a small, initial study, however these encouraging results now show that daraxonrasib and chemotherapy can be effective when used in combination.’

FC9NKT Busy corridor in NHS hospital in England
The study was small but will go on to a larger clinical trial (Picture: Alamy Stock Photo)

She said the team was excited for the larger clinical trial, adding: ‘These findings are part of a growing body of evidence that offers real hope to people with advanced pancreatic cancer.’

She added: ‘The UK Government must ensure we build on the momentum we are seeing by increasing investment into pancreatic research and clinical trials, so that more patients can take part in studies that could improve outcomes.

‘It must also ensure there is a rapid pathway to deliver any game-changing new treatments to patients across the UK as soon as they are proven to work.’

More than 11,000 people are diagnosed with pancreatic cancer each year in the UK and more than 10,000 die from it, usually within a few months.

Cancer Research UK chief executive Michelle Mitchell said: ‘This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.

‘More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low.

‘Further research is needed to look at how this drug could be used alongside other therapies to give patients the best chance of beating the disease.’

Add WTX as a Preferred Source on Google

Add as preferred source

Responses

    Sarah Mitchell·

    Great article! This really puts things into perspective. I appreciate the thorough research and balanced viewpoint.

    James Anderson·

    Interesting read, though I think there are some points that could have been explored further. Would love to see a follow-up on this topic.

    Emma Thompson·

    Thanks for sharing this! I had no idea about some of these details. Definitely bookmarking this for future reference.

    Michael Chen·

    Well written and informative. The examples provided really help illustrate the main points effectively.

    Olivia Rodriguez·

    This is exactly what I was looking for! Clear, concise, and very helpful. Keep up the excellent work!

Stay Updated

Get the latest posts delivered right to your inbox.

No spam, unsubscribe at any time.